FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4211203697> ?p ?o ?g. }

• W4211203697 abstract "Although corticosteroids are currently the first-choice drug for thyroid eye disease (TED), in 20-30% of cases, patients show poor or non-existent responses, and when the drug is withdrawn, 10-20% of patients relapse. Thus, in this study, we aimed to investigate the efficacy of the combined use of mycophenolate mofetil (CellCept®) and low dose oral prednisolone in patients with moderate to severe Graves' orbitopathy (GO). For the first time, we investigated the relationship between TED-related parameters and proptosis reduction. In a prospective, non-randomized, interventional case series, 242 patients with moderate-to-severe GO were, assigned to receive oral prednisolone (5 mg/ d) and mycophenolate mofetil (CellCept®) (one 500 mg tablet twice per day according to the therapeutic response). The patients were monitored regularly during the 3rd, 6th, 12th, and 18th month of treatment. The main outcome measures were the clinical activity score (CAS), intraocular pressure (IOP), diplopia, proptosis and visual acuity. We also assessed the relationship between the main outcomes with proptosis changes and time to improvement (months). Adverse effects were recorded during each visit. The clinical response rate increased from 67.7% on the third month to 89.2% on the sixth month, and 94.2% on the 12th month. This therapeutic response continued until the 18th month of follow-up. The CAS responses [disease inactivation (CAS <3)] improved during our study: 70.6% on the third month, 90.0% on the sixth month, and 92.5% at 12th month. These conditions continued until the 18th month of follow-up. Proptosis improvement was 52% on the third month, 71% on the sixth month, 83% on the 12th month, and 87.1% on the 18th month. Changes in IOP and visual acuity were not significant (P = 0.568 and 0.668, respectively). The patient showed significant improvement in the Gorman score. A Shorter duration of treatment was seen in patients with earlier onset of intervention, younger age, and lack of all extraocular muscle (EOM) enlargement on computed tomography (CT) scan (p < 0.05). In addition, a better response (more reduction) in proptosis was related to: younger age at disease, earlier treatment intervention (less interval from the time the diagnosis of moderate-to-severe GO was made until medication initiation), shorter treatment time (less time to improvement), less IOP, lack of EOM enlargement on CT scan, and lack of diplopia (P < 0.05). Adverse events occurred in six patients. Findings show that mycophenolate mofetil (CellCept®) plus low-dose prednisolone can be introduced as a new optimal dosing regimen in GO due to its better effect on chronic complications such as proptosis and diplopia." @default.
• W4211203697 created "2022-02-13" @default.
• W4211203697 creator A5005914583 @default.
• W4211203697 creator A5017159243 @default.
• W4211203697 creator A5024468689 @default.
• W4211203697 creator A5041393973 @default.
• W4211203697 creator A5057400684 @default.
• W4211203697 creator A5068178361 @default.
• W4211203697 creator A5070489338 @default.
• W4211203697 creator A5074512527 @default.
• W4211203697 creator A5074582464 @default.
• W4211203697 creator A5090493145 @default.
• W4211203697 date "2022-02-11" @default.
• W4211203697 modified "2023-10-18" @default.
• W4211203697 title "Mycophenolate Mofetil (CellCept®) in Combination With Low Dose Prednisolone in Moderate to Severe Graves' Orbitopathy" @default.
• W4211203697 cites W1976360844 @default.
• W4211203697 cites W1977133140 @default.
• W4211203697 cites W1984318254 @default.
• W4211203697 cites W1994453026 @default.
• W4211203697 cites W2038106393 @default.
• W4211203697 cites W2052463348 @default.
• W4211203697 cites W2061904336 @default.
• W4211203697 cites W2066663435 @default.
• W4211203697 cites W2068243562 @default.
• W4211203697 cites W2079726869 @default.
• W4211203697 cites W2092951259 @default.
• W4211203697 cites W2120390749 @default.
• W4211203697 cites W2125891330 @default.
• W4211203697 cites W2152080639 @default.
• W4211203697 cites W2169945487 @default.
• W4211203697 cites W2188403101 @default.
• W4211203697 cites W2288910126 @default.
• W4211203697 cites W2321015072 @default.
• W4211203697 cites W2487648087 @default.
• W4211203697 cites W2784798422 @default.
• W4211203697 cites W2786397131 @default.
• W4211203697 cites W2957021860 @default.
• W4211203697 cites W2973648524 @default.
• W4211203697 cites W2995047063 @default.
• W4211203697 cites W3000080240 @default.
• W4211203697 cites W3153696862 @default.
• W4211203697 cites W3161756474 @default.
• W4211203697 cites W3164728515 @default.
• W4211203697 cites W3180184034 @default.
• W4211203697 cites W3183105886 @default.
• W4211203697 cites W4249795250 @default.
• W4211203697 doi "https://doi.org/10.3389/fmed.2022.788228" @default.
• W4211203697 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35223896" @default.
• W4211203697 hasPublicationYear "2022" @default.
• W4211203697 type Work @default.
• W4211203697 citedByCount "5" @default.
• W4211203697 countsByYear W42112036972022 @default.
• W4211203697 crossrefType "journal-article" @default.
• W4211203697 hasAuthorship W4211203697A5005914583 @default.
• W4211203697 hasAuthorship W4211203697A5017159243 @default.
• W4211203697 hasAuthorship W4211203697A5024468689 @default.
• W4211203697 hasAuthorship W4211203697A5041393973 @default.
• W4211203697 hasAuthorship W4211203697A5057400684 @default.
• W4211203697 hasAuthorship W4211203697A5068178361 @default.
• W4211203697 hasAuthorship W4211203697A5070489338 @default.
• W4211203697 hasAuthorship W4211203697A5074512527 @default.
• W4211203697 hasAuthorship W4211203697A5074582464 @default.
• W4211203697 hasAuthorship W4211203697A5090493145 @default.
• W4211203697 hasBestOaLocation W42112036971 @default.
• W4211203697 hasConcept C126322002 @default.
• W4211203697 hasConcept C141071460 @default.
• W4211203697 hasConcept C187212893 @default.
• W4211203697 hasConcept C197934379 @default.
• W4211203697 hasConcept C2776148792 @default.
• W4211203697 hasConcept C2776715498 @default.
• W4211203697 hasConcept C2776804153 @default.
• W4211203697 hasConcept C2778257484 @default.
• W4211203697 hasConcept C2780581723 @default.
• W4211203697 hasConcept C2909935303 @default.
• W4211203697 hasConcept C2911091166 @default.
• W4211203697 hasConcept C71924100 @default.
• W4211203697 hasConceptScore W4211203697C126322002 @default.
• W4211203697 hasConceptScore W4211203697C141071460 @default.
• W4211203697 hasConceptScore W4211203697C187212893 @default.
• W4211203697 hasConceptScore W4211203697C197934379 @default.
• W4211203697 hasConceptScore W4211203697C2776148792 @default.
• W4211203697 hasConceptScore W4211203697C2776715498 @default.
• W4211203697 hasConceptScore W4211203697C2776804153 @default.
• W4211203697 hasConceptScore W4211203697C2778257484 @default.
• W4211203697 hasConceptScore W4211203697C2780581723 @default.
• W4211203697 hasConceptScore W4211203697C2909935303 @default.
• W4211203697 hasConceptScore W4211203697C2911091166 @default.
• W4211203697 hasConceptScore W4211203697C71924100 @default.
• W4211203697 hasLocation W42112036971 @default.
• W4211203697 hasLocation W42112036972 @default.
• W4211203697 hasLocation W42112036973 @default.
• W4211203697 hasLocation W42112036974 @default.
• W4211203697 hasOpenAccess W4211203697 @default.
• W4211203697 hasPrimaryLocation W42112036971 @default.
• W4211203697 hasRelatedWork W1967537743 @default.
• W4211203697 hasRelatedWork W1986295912 @default.
• W4211203697 hasRelatedWork W2056236064 @default.
• W4211203697 hasRelatedWork W2328795430 @default.
• W4211203697 hasRelatedWork W23857334 @default.
• W4211203697 hasRelatedWork W23937398 @default.

• next